CNC heads into the back half of May with the analyst repricing still running — and the short-seller retreat now effectively complete.
The most notable development this week is on the Street. Deutsche Bank's George Hill upgraded CNC to Buy from Hold this morning, lifting his target from $53 to $80 — a 51% move that puts his number well above the current consensus mean of $54.94. That $80 target implies roughly 35% upside from Tuesday's close of $59.15. Mizuho's Ann Hynes also raised her target today, moving from $50 to $58 while maintaining Neutral. The direction of travel is clear: even the holdouts are resetting their numbers higher. Since the April 28 earnings beat, targets have risen at virtually every firm that covers the stock. The analyst recommendation divergence factor ranks at the 97th percentile — one of the widest positive gaps across the market right now. EPS momentum reinforces the picture, with the 30-day reading in the 92nd percentile and the 90-day in the 87th.
The short-selling story has moved firmly into the rear-view mirror. Short interest has fallen 28% over the past week to 2.3% of the free float — barely above incidental levels. The decline started immediately after the April 28 surge, with peak short positions of roughly 16 million shares in early May now unwinding toward 11 million. Borrow costs confirm the retreat: the cost to borrow is running near 0.23%, down 69% over the past month, and availability has expanded dramatically — now at 5,704% of estimated short interest, meaning shares are abundantly available to borrow for anyone who still wants to build a position. The ORTEX short score has eased to 30.7 from a recent peak of 33.8 on May 12. There is no squeeze pressure, no borrow tension, and no sign of residual conviction on the short side.
Options positioning is mildly constructive but not stretched. The put/call ratio is running at 0.36, just above its 20-day mean of 0.34 and only 0.6 standard deviations above average. The 52-week high on the PCR is 1.45 — the current reading is nowhere near defensive territory. Call activity continues to dominate, consistent with a market that has largely accepted the re-rating rather than hedging against it.
The bull and bear cases are now well defined by the data. Bulls point to the Medicaid HBR improvement to 93.4%, Medicare membership crossing 1 million, and average premium rates in the mid-5% range for the September and October cohorts. Bears flag the drop in low-cost Silver portfolio exposure — from 55% in 2025 to an expected 42% in 2026 — along with a commercial HBR at 89.9% that came in below expectations, and ongoing regulatory risk in government-sponsored plan markets. The valuation re-rating has been sharp: the P/E multiple has risen by 3.7 points over the past 30 days to 15.3x, and price-to-book is up 0.35 over the same period to 1.23x. Neither multiple looks stretched in absolute terms, but both reflect a stock that has moved significantly in a short window.
Institutional ownership is passive-heavy, which limits the read-through from the holder list. Vanguard and BlackRock together hold roughly 20% of shares, with AQR adding a notable 2.1 million shares in the last reported period. Two Sigma added over 4.3 million shares as of March 31 — a meaningful build from a quant fund that suggests systematic momentum models have been flagging the name. Insider activity has been the one cautious note: the CEO and CFO both sold in mid-March at $34.45, well below today's price, though those sales look more like scheduled disposals than a fundamental signal given the timing.
With Q2 results not due until July 28, the next few weeks are about whether the Street continues to converge toward Deutsche Bank's $80 target or whether the consensus mean stays anchored around $55 — still below where CNC is already trading.
See the live data behind this article on ORTEX.
Open CNC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
